Literature DB >> 20488458

Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and meta-analysis.

Javier Costas1, Julio Sanjuán, Ramón Ramos-Ríos, Eduardo Paz, Santiago Agra, José Luis Ivorra, Mario Páramo, Julio Brenlla, Manuel Arrojo.   

Abstract

Catechol-O-methyltransferase (COMT) has been largely studied in relation to schizophrenia susceptibility. Most studies focused on the functional single nucleotide polymorphism (SNP) rs4680 that causes a substitution of Val by Met at codon 158 of the COMT protein. Recent meta-analyses do not support an association between allelic variants at rs4680 and schizophrenia. However, the putative role of overdominance has not been tested in meta-analyses, despite its biological plausibility. In this work, we tested the overdominant model in two Spanish samples (from Valencia and Santiago de Compostela), representing a total of 762 schizophrenic patients and 1042 controls, and performed a meta-analysis of the available studies under this model. A total of 51 studies comprising 13,894 schizophrenic patients and 16,087 controls were included in the meta-analysis, that revealed a small but significant protective effect for heterozygosity at rs4680 (pooled OR=0.947, P=0.023). Post-hoc analysis on southwestern European samples suggested a stronger effect in these populations (pooled OR=0.813, P=0.0009). Thus, the COMT functional polymorphism rs4680 contributes to schizophrenia genetic susceptibility under an overdominant model, indicating that both too high and too low levels of dopamine (DA) signalling may be risk factors. This effect can be modulated by genetic background. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488458     DOI: 10.1016/j.jpsychires.2010.04.021

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  23 in total

1.  Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

Authors:  Vicki L Ellingrod; Stephan F Taylor; Gregory Dalack; Tyler B Grove; Michael J Bly; Robert D Brook; Sebastian K Zöllner; Rodica Pop-Busui
Journal:  J Clin Psychopharmacol       Date:  2012-04       Impact factor: 3.153

Review 2.  Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome.

Authors:  Nicole Philip; Anne Bassett
Journal:  Behav Genet       Date:  2011-05-15       Impact factor: 2.805

3.  Dopaminergic, serotonergic, and oxytonergic candidate genes associated with infant attachment security and disorganization? In search of main and interaction effects.

Authors:  Maartje P C M Luijk; Glenn I Roisman; John D Haltigan; Henning Tiemeier; Cathryn Booth-Laforce; Marinus H van Ijzendoorn; Jay Belsky; Andre G Uitterlinden; Vincent W V Jaddoe; Albert Hofman; Frank C Verhulst; Anne Tharner; Marian J Bakermans-Kranenburg
Journal:  J Child Psychol Psychiatry       Date:  2011-07-13       Impact factor: 8.982

4.  No association of catechol-O-methyltransferase polymorphisms with schizophrenia in the Han Chinese population.

Authors:  Fuquan Zhang; Chenxing Liu; Yaguang Chen; Lifang Wang; Tianlan Lu; Hao Yan; Yanyan Ruan; Weihua Yue; Dai Zhang
Journal:  Genet Test Mol Biomarkers       Date:  2012-09

Review 5.  The Role of a Catechol-O-Methyltransferase (COMT) Val158Met Genetic Polymorphism in Schizophrenia: A Systematic Review and Updated Meta-analysis on 32,816 Subjects.

Authors:  Thelma Beatriz González-Castro; Yazmin Hernández-Díaz; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Carlos Alfonso Tovilla-Zárate; Ana Fresan
Journal:  Neuromolecular Med       Date:  2016-03-28       Impact factor: 3.843

6.  Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study.

Authors:  Alexis C Edwards; Silviu-Alin Bacanu; Tim B Bigdeli; Arden Moscati; Kenneth S Kendler
Journal:  Schizophr Res       Date:  2016-06-20       Impact factor: 4.939

7.  No association between Val158Met of the COMT gene and susceptibility to schizophrenia in the Syrian population.

Authors:  Bassam Lajin; Amal Alachkar; Abdul Rezzak Hamzeh; Roula Michati; Hamid Alhaj
Journal:  N Am J Med Sci       Date:  2011-04

8.  No association between catechol-o-methyltransferase Val108/158Met polymorphism and schizophrenia or its clinical symptomatology in a Mexican population.

Authors:  Carlos Tovilla-Zárate; Beatriz Camarena Medellín; Ana Fresán; Lilia López-Narváez; Thelma Beatriz Gonzalez Castro; Isela Juárez Rojop; Julián Ramírez-Bello; Alma Genis; Humberto Nicolini
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

9.  COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers.

Authors:  A I Herman; P I Jatlow; J Gelernter; J B Listman; M Sofuoglu
Journal:  Pharmacogenomics J       Date:  2013-03-05       Impact factor: 3.550

10.  A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia.

Authors:  Jay P Singh; Jan Volavka; Pál Czobor; Richard A Van Dorn
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.